trending Market Intelligence /marketintelligence/en/news-insights/trending/asBS-6pmT_9FAXfgkzwc0A2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Merck's Keytruda fails to improve survival in triple-negative breast cancer

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


Merck's Keytruda fails to improve survival in triple-negative breast cancer

Merck & Co. Inc.'s blockbuster immuno-oncology drug Keytruda failed to meet its main goal of improving survival in certain breast cancer patients compared to chemotherapy in a late-stage study.

The study, named Keynote-119, evaluated the anti-PD1 therapy alone in metastatic triple-negative breast cancer after patients had already received prior treatments that did not show benefit.

Secondary goals were not tested because the primary goal was not met, the Kenilworth, N.J.-based company stated in a May 20 press release.

Merck will report the results of the trial at an upcoming medical meeting.

Keytruda, also known as a checkpoint inhibitor that activates T-cells in the body, is approved for multiple cancer indications and is being tested in over 900 clinical trials.

SNL Image